Comparison of ixekizumab with ustekinumab in patients with baseline PASI>15 and/or at-least 3previous-non-biologic-therapies-treatment-failures: 24-week post-hoc-analysis from a randomized trial (IXORA-S;NCT02561806)

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis

Essential information for estimating total PASI: A model developed from phase 3 trials of ixekizumab (IXE) for application in teledermatology

Ixekizumab provides sustained improvement in signs and symptoms in patients with active psoriatic arthritis: Results from a phase 3 trial

Matching-adjusted indirect comparisons of ixekizumab and secukinumab using etanercept and ustekinumab bridge comparators

To give or not to give, that is still the question: A 10 year TEN experience at NSW referral centre

Blue vitiligo: A case report

“Idiopathic hyperkeratotic migratory flexural erythema” successfully treated with oral amoxicillinclavulanic acid: A report of 3 cases

Sustained improvement in patient-reported outcomes with continued apremilast treatment over 104 weeks in patients with moderate to severe psoriasis

A hedgehog opportunity: Management of multiple basal cell carcinomas in a patient treated for acne with facial radiation therapy

Treatment of Hailey-Hailey disease with botulinum toxin

Ultrasound in the diagnosis and staging of hidradenitis suppurativa